Simulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day

Reuters01-22

<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Unveils AI-Enabled Drug Development Platform at 2026 Investor Day

Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121307543) on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605438773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605438773","market":"fut","top_or_hot":-1,"title":"Simulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Unveils AI-Enabled Drug Development Platform at 2026 Investor Day\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121307543) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Unveils AI-Enabled Drug Development Platform at 2026 Investor Day\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121307543) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL2tjlyl:1","article_id":"2605438773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605438773","pubTimestamp":1769029606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","SLP":"Simulations Plus"},"translate_title":"Simulations Plus在2026年投资者日推出人工智能药物开发平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLP":0.9},"content_text":"Simulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day\n    \n\n        Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121307543) on January 21, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605438773","isCrawlerRequest":true}